Weekly Investment Analysts’ Ratings Changes for Guardian Pharmacy Services (GRDN)

Several analysts have recently updated their ratings and price targets for Guardian Pharmacy Services (NYSE: GRDN):

• 5/11/2026 – Guardian Pharmacy Services was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 5/11/2026 – Guardian Pharmacy Services was downgraded by Zacks Research from “strong-buy” to “hold”.
• 5/9/2026 – Guardian Pharmacy Services was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/7/2026 – Guardian Pharmacy Services had its price target raised by Oppenheimer Holdings, Inc. from $38.00 to $43.00. They now have an “outperform” rating on the stock.
• 4/27/2026 – Guardian Pharmacy Services is now covered by Bank of America Corporation. They set a “buy” rating and a $42.00 price target on the stock.
• 4/25/2026 – Guardian Pharmacy Services was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 4/13/2026 – Guardian Pharmacy Services had its price target raised by Truist Financial Corporation from $38.00 to $43.00. They now have a “buy” rating on the stock.
• 4/11/2026 – Guardian Pharmacy Services was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 3/30/2026 – Guardian Pharmacy Services is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $44.00 price target on the stock.
• 3/27/2026 – Guardian Pharmacy Services had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 3/18/2026 – Guardian Pharmacy Services was upgraded by Zacks Research from “hold” to “strong-buy”.

Insider Activity at Guardian Pharmacy Services

In other news, insider Fred Burke sold 671,432 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $19,928,101.76. Following the sale, the insider directly owned 840,413 shares in the company, valued at approximately $24,943,457.84. The trade was a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John Ackerman sold 1,103,364 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $32,747,843.52. Following the sale, the director owned 345,123 shares in the company, valued at approximately $10,243,250.64. This trade represents a 76.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 9,726,405 shares of company stock valued at $288,679,700. Corporate insiders own 32.96% of the company’s stock.

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.